Drug recall · August 3, 2016
mitoXANTRONE Injection USP recall
Why: Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.
- Lots / codes
Lot # 31318659B, Exp 02/17
- Quantity
- 2,506 vials
- Company
- Teva North America, Horsham, PA
- Distribution
- Nationwide
- Initiated
- May 31, 2016 · Voluntary: Firm initiated
- Classified
- July 28, 2016
- Reported
- August 3, 2016
- Ended
- May 8, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Mitoxantrone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.